Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Analysis of cerebrospinal fluid soluble interleukin-2 receptor α as a biomarker for autoimmune glial fibrillary acidic protein astrocytopathy.

Created on 17 Nov 2026

Authors

Kotaro Haruna, Junko Ishii, Hajime Yoshimura, Michi Kawamoto

Published in

Immunological medicine. Pages 1-14. Nov 16, 2026. Epub Nov 16, 2026.

Abstract

Autoimmune GFAP astrocytopathy (GFAP-A) has several proposed biomarkers, but few are readily available in routine practice. This single-center retrospective case-control study evaluated CSF soluble IL-2R α (sIL-2R), a readily measurable marker of T-cell activation, as a clinically accessible marker reflecting CNS inflammatory activity in GFAP-A in the context of autoimmune encephalitis (AE). CSF sIL-2R-related parameters were measured in patients with GFAP-A, MOGAD with encephalitis, anti-NMDAR encephalitis, anti-LGI1 encephalitis, and non-inflammatory neurological diseases (NINDs). sIL-2R was measured using chemiluminescent enzyme immunoassay. CSF, CSF/serum sIL-2R quotient (QsIL-2R), sIL-2R index (QsIL-2R/Qalbumin), and Qalbumin were compared across the groups, and longitudinal changes were examined. CSF sIL-2R, QsIL-2R, sIL-2R index, and Qalbumin levels were elevated in patients with GFAP-A compared with those in patients with NINDs and other AE groups. CSF sIL-2R discriminated GFAP-A from other selected AE subtypes. CSF predominance of sIL-2R levels was characteristic of GFAP-A. In GFAP-A, sIL-2R quotient diagrams showed QsIL-2R elevations disproportionate to Qalbumin and CSF sIL-2R levels decreased following immunotherapy alongside clinical improvements. These findings suggest that CSF sIL-2R may complement existing biomarkers by supporting the identification of GFAP-A among patients with suspected AE after exclusion of mimics and by providing adjunctive information on treatment-responsive immune activity in GFAP-A.

PMID:
43038131
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement